Navigation Links
Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
Date:1/11/2008

HORSHAM, PA (January 11, 2008): Nucleonics, Inc., a privately held biotechnology company focused on the development of novel RNA interference (RNAi)-based therapeutics, announced today that the company has begun treating patients in a Phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection, NUC B1000.

NUC B1000 (http://www.nucleonicsinc.com/products/hepb.html) is an expressed interfering RNA (eiRNA)-based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. Each of the four siRNAs targets a different sequence of the HBV genome, collectively leading to the potential destruction or elimination of all RNA species produced by HBV within an infected cell. The result is a potent antiviral effect designed for efficacy against all HBV genotypes, including drug resistant strains. Additionally, unlike currently available HBV therapeutics, NUCB1000 is designed to specifically reduce viral antigen load in addition to viral titer, thereby reducing the destructive effects of hepatitis and increasing the potential for resolution of viral infection.

Despite the widespread availability of multiple prophylactic vaccines against HBV, chronic HBV infection remains a public health problem around the world that can lead to such serious diseases as cirrhosis, fibrosis and liver cancer in up to one-third of patients, said Principal Investigator, Robert G. Gish, M.D, Medical Director, Liver Transplant Program and Chief, Division of Hepatology and Complex GI, California Pacific Medical Center, San Francisco. Current anti-HBV drug therapies are of limited effectiveness and are not often used in patients with mild to moderate disease due to risks of developing drug resistance. Thus there is significant need for new treatments that can improve
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
2. Possible hepatitis C vaccine
3. Who will recover spontaneously from hepatitis C virus infection
4. Clearance of hepatitis C viral infection after liver transplantation
5. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
6. New clinical data shows chromium picolinate improves cognitive function
7. Study of African traditional medicine will begin world-first clinical trial
8. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
9. Cleveland Clinic leading clinical program to improve early-stage lung cancer detection
10. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
11. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... gap in stillbirth rates between indigenous and non-indigenous women ... still at risk of stillbirth due to preventable causes, ... September) in BJOG: An International Journal of Obstetrics ... study used data from the Queensland Perinatal Data Collection ... 2011. It aimed to assess the differences in stillbirth ...
(Date:9/2/2014)... Earthquake rupture through a U.S. suburb , Observations ... Davis in the hours and days after the August ... why the earthquake caused so much damage in the ... blog, hosted by the American Geophysical Union. , ... The Next Places to Direct Our Curiosity , ...
(Date:9/2/2014)... will present the prestigious Parker/Gentry Award to Mr. Rhett ... conservation awareness. The Parker/Gentry Award is given annually by ... organization whose efforts have had a significant impact on ... can serve as a model to others. , Rhett ... and conservation news website that draws more than 2 ...
Breaking Biology News(10 mins):Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 2Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 3This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2
... ,URBANA A University of Illinois study reports a promising ... who have developed resistance to chemotherapy. U of I ... lunasin binds to a specific receptor in highly metastatic colon ... "When lunasin was used in combination with the chemotherapy drug ...
... Cystic fibrosis (CF), a chronic disease that clogs the ... by a genetic defect in a chloride channel called ... not fully understand how or why this defect occurs, ... Children (SickKids) in Toronto, Ontario, Canada has found a ...
... at Nanjing university present a rather striking finding that plant ... the route of food-intake. Moreover, once inside the host, they ... regulate host physiology. MicroRNAs are a class of ... MicroRNAs bind to target messenger RNAs to inhibit protein ...
Cached Biology News:Soy peptide + chemo drug block colon cancer's spread to liver 2Unraveling a new regulator of cystic fibrosis 2We are not only eating 'materials', we are also eating 'information' 2
(Date:9/3/2014)... Korea (PRWEB) September 03, 2014 ... Seoul Viosys (C.E.O. Jaejo Kim, http://www.seoulviosys.com ... launched the Viophoton technology for the first ... utilizes functional photons of specific energy which ... produce life-extending efficacy for food preservation applications. ...
(Date:9/2/2014)... LONDON , Sept. 2, 2014 ... Human Reproductive Technologies: Products and Global ... STUDY GOALS AND OBJECTIVES The objective of ... look at the market for reproductive technologies and ... and indication. The products in some markets are ...
(Date:9/2/2014)... DALLAS , Sept. 2, 2014 /PRNewswire-iReach/ -- ... Sodium Bicarbonate Industry" and "2014 Market Research Report ... research database. Photo - http://photos.prnewswire.com/prnh/20140902/141873 ... on Global Sodium Bicarbonate Industry" is a professional ... and Global Sodium Bicarbonate market. The ...
(Date:9/2/2014)... The Little Company of Mary Hospital in ... 290,000 square-foot West Pavilion patient tower, which included the ... Products for the nurse’s lounge near the maternity ward. ... Mary Hospital’s $180 million, four-year Campus Transformation project ... of the West Pavilion tower to the North Pavilion, ...
Breaking Biology Technology:Human Reproductive Technologies: Products and Global Markets 2Human Reproductive Technologies: Products and Global Markets 3Human Reproductive Technologies: Products and Global Markets 4Human Reproductive Technologies: Products and Global Markets 5Human Reproductive Technologies: Products and Global Markets 6Human Reproductive Technologies: Products and Global Markets 7Human Reproductive Technologies: Products and Global Markets 8Human Reproductive Technologies: Products and Global Markets 9Human Reproductive Technologies: Products and Global Markets 10Human Reproductive Technologies: Products and Global Markets 11Human Reproductive Technologies: Products and Global Markets 12Human Reproductive Technologies: Products and Global Markets 13Human Reproductive Technologies: Products and Global Markets 14Human Reproductive Technologies: Products and Global Markets 15Human Reproductive Technologies: Products and Global Markets 16Human Reproductive Technologies: Products and Global Markets 17Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 2Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 3Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 4Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 5Tufftec® Lockers from Scranton Products Selected by Little Company of Mary Hospital Near Chicago to Create an Uplifting Environment 2Tufftec® Lockers from Scranton Products Selected by Little Company of Mary Hospital Near Chicago to Create an Uplifting Environment 3
... , , KENILWORTH, N.J., July ... results for the 2009 second quarter. , , ... have given us the strength to again power through tough challenges - ... said Fred Hassan, chairman and CEO. , , ...
... ... Accreditation and Compliance Excellence Solution , ... San Francisco, CA (PRWEB) July 21, 2009 -- Quantros, a leading ... industry , announced today the highly positive results East Jefferson General Hospital (EJGH) has ...
... ... Europe, Canada, and Russia requiring confidential, direct buyer representation for a ... Board Certified real estate attorney and Lic. Real Estate Broker, Christian ... broker and real estate attorney exclusively for premium property buyers, greatly ...
Cached Biology Technology:Schering-Plough Reports Financial Results for 2009 Second Quarter 2Schering-Plough Reports Financial Results for 2009 Second Quarter 3Schering-Plough Reports Financial Results for 2009 Second Quarter 4Schering-Plough Reports Financial Results for 2009 Second Quarter 5Schering-Plough Reports Financial Results for 2009 Second Quarter 6Schering-Plough Reports Financial Results for 2009 Second Quarter 7Schering-Plough Reports Financial Results for 2009 Second Quarter 8Schering-Plough Reports Financial Results for 2009 Second Quarter 9Schering-Plough Reports Financial Results for 2009 Second Quarter 10Schering-Plough Reports Financial Results for 2009 Second Quarter 11Schering-Plough Reports Financial Results for 2009 Second Quarter 12Schering-Plough Reports Financial Results for 2009 Second Quarter 13Schering-Plough Reports Financial Results for 2009 Second Quarter 14Schering-Plough Reports Financial Results for 2009 Second Quarter 15Schering-Plough Reports Financial Results for 2009 Second Quarter 16Schering-Plough Reports Financial Results for 2009 Second Quarter 17Schering-Plough Reports Financial Results for 2009 Second Quarter 18Schering-Plough Reports Financial Results for 2009 Second Quarter 19Schering-Plough Reports Financial Results for 2009 Second Quarter 20Schering-Plough Reports Financial Results for 2009 Second Quarter 21Schering-Plough Reports Financial Results for 2009 Second Quarter 22Schering-Plough Reports Financial Results for 2009 Second Quarter 23Schering-Plough Reports Financial Results for 2009 Second Quarter 24Schering-Plough Reports Financial Results for 2009 Second Quarter 25Schering-Plough Reports Financial Results for 2009 Second Quarter 26Schering-Plough Reports Financial Results for 2009 Second Quarter 27Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance 2Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance 3Miami Beach Real Estate Attorney Opens Miami Real Estate Brokerage for International Luxury Miami Beach Condo Buyers From Distressed Sellers 2Miami Beach Real Estate Attorney Opens Miami Real Estate Brokerage for International Luxury Miami Beach Condo Buyers From Distressed Sellers 3
... unique human proteins on a 1x3 ... a cross section of all cellular ... high-quality results. Additional control proteins and ... validity and reproducibility., ,UNIchip protein microarrays ...
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, all ... Ontology classification, are arrayed in quadruplicate ... and a specific chip layout guarantee ...
... The Sub-Plates are E.Coli glycerol stocks ... well contains 50 cDNA clones with approximately ... of the a master plate well, the ... 96-well PCR to identify the positive well(s). ...
... The TNT Coupled Reticulocyte Lysate ... eukaryotic in vitro translations: a single-tube, ... Systems greatly simplify the process and ... in vitro translation results. Standard rabbit ...
Biology Products: